This journal is Acquired immunodeficiency syndrome (AIDS) is a life-threatening disease which is a collection of symptoms and infections caused by a retrovirus, human immunodeficiency virus (HIV). There is currently no curative treatment and therapy is reliant on the use of existing anti-retroviral drugs. Pharmacoinformatics approaches have already proven their pivotal role in the pharmaceutical industry for lead identification and optimization. In the current study, we analysed the binding preferences and inhibitory activity of HIV-integrase inhibitors using pharmacoinformatics. A set of 30 compounds were selected as the training set of a total 540 molecules for pharmacophore model generation. The final model was validated by statistical parameters and further used for virtual screening. The best mapped model (R = 0.940, rmsd = 2.847, Q 2 = 0.912, se = 0.498, R 2 pred = 0.847 and r 2 m (test) = 0.636) explained that two hydrogen bond acceptor and one aromatic ring features were crucial for the inhibition of HIV-integrase. From virtual screening, initial hits were sorted using a number of parameters and finally two compounds were proposed as promising HIV-integrase inhibitors. Drug-likeness properties of the final screened compounds were compared to FDA approved HIV-integrase inhibitors. HIV-integrase structure in complex with the most active and final screened compounds were subjected to 50ns molecular dynamics (MD) simulation studies to check comparative stability of the complexes. The study suggested that the screened compounds might be promising HIV-integrase inhibitors. The new chemical entities obtained from the NCI database will be subjected to experimental studies to confirm potential inhibition of HIV integrase.
Introduction
Human immunodeficiency virus (HIV) is the aetiological agent of acquired immunodeficiency syndrome (AIDS) which destroys the immune system of the body leaving the victim vulnerable to infections, malignancies and neurological disorder. Owing to its rapid spread it has become a serious global threat and there is no curative treatment for this fatal disease. According to statistics by World Health Organization (WHO), a total of 37.20 million people are living with AIDS and 1.70 million people died in 2013 alone.
Currently, there are 3 categories of therapeutic anti-HIV drugs based on their inhibitory mechanisms 1 and these include nucleoside reverse transcriptase inhibitors (NRTIs) 2 , non-nucleoside reverse transcriptase inhibitors (NNRTIs) 3 , and protease inhibitors (PIs) 4, 5 . To date the highly active antiretroviral therapy (HAART) 6 which is combined therapy using the above classes of inhibitors is widely used for patients with advance infection but has failed to eradicate the virus. HAART is intended to slow down viral replication and lower the patient's total burden of HIV infection, but this treatment is not entirely cost effective and is often out of reach of people worldwide. The genome of the HIV encodes for three enzymes viz. the protease, reverse transcriptase and integrase. The integrase is a 32 kDa enzyme made of three functional domains included an N-terminal domain, catalytic core domain and a less conserved C-terminal domain 7, 8 . The HIV integrase has no equivalent counterpart or sequence homologue in the human host cell and consequently it can be considered as an attractive drug target 9 . After the approval of Raltegravir 10 as anti-HIV drug several integrase inhibitors emerged as promising class of therapeutics for the treatment of AIDS. Raltegravir and several other inhibitors have been identified to possess anti-HIV integrase activity but these have adverse effects on prolonged use and the development of drug resistance drives the need to explore new novel and potential chemical scaffolds for the treatment of AIDS.
The computational methods in drug discovery collectively termed pharmacoinformatics, includes structure activity relationship (SAR), pharmacophore, virtual screening and molecular docking and these have proven their pivotal role in the pharmaceutical industry for lead identification and optimization. Several research groups worldwide identified integrase inhibitors [11] [12] [13] [14] [15] [16] [17] using pharmacoinformatics approaches for potential application for HIV therapy. Consistent with the objective of developing new potent and less toxic integrase inhibitors the current research explores the binding preferences of the inhibitory molecules of HIV integrase in terms of space modelling study and virtual screening along with molecular docking and molecular dynamics.
A pharmacophore model is an collection of steric and electronic features and provides an intuitive way of depicting and understanding the binding properties of small molecules along with an explanation of optimum supra-molecular interactions with a precise biological target , to activate (or block) its biological response 18, 19 . It can also be defined that the pharmacophore idea is based on the kinds of interaction observed in molecular appreciation, i.e., hydrophobic, hydrogen bonding, and charge interaction. For the HIV integrase inhibitors the hydrogen bond acceptor (HBA) and donor (HBD), hydrophobic (H) and aromatic ring (RA) pharmacophore features were found to be the important functional features associated with the selectivity and potency. The pharmacophore models are widely used in the field of drug discovery by providing valuable information to study SAR and reveals the mechanism of ligand-target relationship by deducing the nature of functional groups and non-covalent bonding patterns 20 . It can also be used in virtual screening to identify potential molecules, predict the activity of the newly synthesized compound before animal experiment; or understand the possible mechanism of action 21, 22 . In the current study, an attempt was made to identify the pharmacophore hypothesis using the HypoGen module 23 based on key chemical features of HIV-integrase inhibitors with inhibition constant covering a satisfactory wide range of magnitude. The model was validated using several statistical approaches including Fischer's randomization and test set prediction. The validated model was utilized for the virtual screening to select the virtual hits from structural database. The molecular docking study was also performed to elucidate the binding interactions and preferred orientation of proposed potential molecules. The potential of the work is displayed by the identification of two potential lead molecules as integrase inhibitors. Finally, the molecular dynamics study was performed to analyse stability and precise binding interactions of the screened molecules inside the receptor cavity of HIV integrase.
Materials and methods
At present, several popular commercial and freeware packages are used for ligand-based method to derive 3D pharmacophore models and also help in estimation of biological activities. Here we used Discovery Studio 4.0 (DS) 24 for the 3D QSAR pharmacophore, virtual screening and molecular docking studies. This is commercially available software containing several module packages and widely used in pharmacoinformatics drug discovery [25] [26] [27] [28] 
Validation of pharmacophore model
In order to check the predictivity and applicability as well as robustness of the pharmacoinformatics model, the pharmacophore hypotheses developed were validated by five different methods, (1) internal validation, (2) cost function analysis, (3) Fischer's randomization test, (4) test set prediction and (5) decoy set.
Internal validation
Leave low se explained better predictive ability 36 .
Another parameter, the modified r 2 (r 2 m(LOO) ) developed by Roy et al. 37, 38 was calculated to confirm the good predictive ability of the training set molecules. This parameter measure the degree of deviation of the predicted activity from the observed ones. It was stated that model may be considered with r 2 m(LOO) >0.5.
Cost function analysis
To select the final pharmacophore model several statistical Please do not adjust margins Please do not adjust margins illustrated that the higher (>60) cost difference (∆cost = null costtotal cost) indicted that the hypothesis does not reflect a chance correlation.
Fischer's randomization test
In order to check the strong relationship between the chemical compound and the biological activity of the training set molecules the Fischer's randomization test was performed. In this method, the biological activity was scrambled and assigned new values. After that the pharmacophore hypotheses were generated with new values of activity using the original pharmacophoric features and constraints used to generate the original pharmacophore hypotheses. If the randomization run generates improved correlation coefficient and/or better statistical parameters than the original hypothesis may be considered to be developed by chance.
Different number of spreadsheets are generated based on the statistical significance randomization run. The statistical significance is given by following equation.
Where, a denotes the number of hypotheses with a total cost less than the best hypothesis, whereas b implies a collection of HypoGen runs and random runs. For example, at 95% confidence level total number of random spreadsheet are generated as 19 (b = 20) and each generated spreadsheet is submitted to HypoGen using the same parameters as the initial run. In the present study, the developed pharmacophore model was tested at 95% confidence level which produced 19 spreadsheets.
Test set prediction
The ability to judge the external predictivity of the model beyond the training set molecules is an important step which verifies ability of prediction of test compounds. Accordingly, in the present work 410 test compounds were predicted using the developed pharmacophore model by Ligand Pharmacophore Mapping protocol in DS, given in 
Molecular Dynamics
In order to perform MD simulation and part of the analysis of the trajectories the AMBER 12 48 was used for the selected docked poses. The generalized amber force field was used for preparation of both ligand and receptor. A rectangular box of TIP3P water was created with boundary of 10Å around the each system. Each system was minimized for 500 steps of each conjugate gradient and steepest descent method. The system was heated at constant volume and temperature of 10 to 150K with the Langevin thermostat over the course of 100ps with 25kcal mol -1 Å -2 .
Drug-likeness analysis of screened compounds
In order to compare the drug-likeness of the screened compounds 
Results and Discussion
The HypoGen module was used to develop the pharmacophore model based on training set (n tr = 30) compounds selected from the whole dataset. The training set molecules are depicted in the Fig. 1 (H1 -H30) Table 1 . For selection of best pharmacophore model Debnath's 21, 49 analysis states that model should have the less rmsd, high correlation coefficient, lowest cost value and highest cost difference. In the current study, the predictivity of first hypothesis (Hypo 1) was confirmed by Debnath's method 21, 49 . A valid hypothesis should have the overall cost of the hypothesis different from the null cost and near to the fixed cost, and it is reported that the cost difference (∆cost = null cost -total cost) in the range of 40-60 bits explains the probability of the predictive correlation of 75-90%, while the ∆cost more than 60 bits means the hypothesis has a correlation probability of greater than 90% 50 . In the selected pharmacophore in the present study, the cost difference for Hypo1 (Table 1 ) was found to be 914.671, i.e. much more than 60 bits, explaining that selected model has a >90% chance of being able to select HIV integrase inhibitors. The best model (Hypo1, Fig. 2a ) obtained with critical features of two 'HBA' (HBA1 and HBA2) and one 'RA' and portrayed in Fig. 2a after mapping with most active compound of the dataset. In order to nullify over-prediction of the bioactivity for inactive molecules The algorithm identifies areas of space that are occupied by inactive ligands and strategically places excluded volumes (ev) in these regions to reduce the number of inactives that can map the pharmacophore. It was observed that ten ev factors were critical for the inhibitory activity of HIV integrase. The model with ev is delineated in Fig. 2b . Quality of the selected hypothesis was Table 2 and Fig. 3 . It was observed that best hypothesis gives Q 2 of 0.912 and se of 0.498.
The high Q 2 and low se of the selected model suggested that model is robust in nature. The most active compound of the dataset was mapped in the best model (Hypo 1 in Table 2 ) and depicted in Fig. 2a . Mapped features suggested that amine and hydroxyl group present in the six membered non-aromatic ring as HBA1 and HBA2. The aromatic ring presence in the molecular system of most active compounds was found to be important as ring aromatics factor. Gupta et al. 16, 51 developed QSAR, pharmacophore and comparative molecular field analysis (CoMFA) studies on curumine derivatives as HIV-1 integrase inhibitors. Both studies found that hydrophobicity and ring aromatic along with hydrogen bond acceptor and donor were crucial for inhibitory activity. These findings are comparable with the outcomes of current research. Therefore it can be postulated that to design or synthesize new chemical entities of HIV integrase inhibitors HBA and R factors with critical inter-feature distances ( Fig. 2c ) will be crucial factors.
Test set prediction
Any robust pharmacoinformatics model should have the capability to predict the activities of the compounds other than training set.
Out of whole dataset, 510 compounds were considered as test set and the activity (IC 50 ) converted into logarithm value (pIC 50 ) and
given in Table S5 in supplementary file and Fig. 3 (1). The correlation values of all 19 spreadsheets obtained and depicted in the Table 3 indicated that not a single value obtained after randomizationproduced hypotheses that exhibited predictive powers similar to or better than that of hypo 1 (Table 1) . From Table 3 , the average of correlation coefficient for all 19 trials was found to be 0.642. It was also observed that the total costs of randomized runs were much higher than the total cost of Hypo 1.
The total cost of Hypo 1 and all other 19 random hypotheses is depicted in the Fig. 4 and Table 3 . The above discussion undoubtedly demonstrated that the selected pharmacophore model was not produced by chance. Fig. 4 Comparison of the total costs of Hypo 1 and 19 random hypotheses generated in the Fischer's randomization test. Please do not adjust margins Please do not adjust margins that clearly indicated more true positives have been verified. The enrichment factor (EF 1%) and Boltzmann-enhanced discrimination of ROC were calculated. Average EF 1 % value for pharmacophore model was found to be 9.80 which indicated that model has identified active compounds very well and the top 1% hit is enriched with active compounds. The average BEDROC was obtained as 0.85 which signifies that the top hits is not only enriched with active compounds but also ranked higher than decoy.
Decoy set
The abovementioned results of decoy validation strongly suggest that the developed pharmacophore features in the selected model are perfectly acceptable for the mapping of HIV-integrase inhibitors 
Virtual screening
In order to find potential molecules that are HIV integrase inhibitors virtual screening is a powerful technique and also effective as an alternative to high-throughput screening methodologies. For this purpose the validated pharmacoinformatics models including QSAR, pharmacophore or molecular docking can be used to search the molecular database for lead identification. The Hypo 1 and hyporefined of Hypo 1 (Fig. 2a and 2b) The molecular docking study ( Fig. 7 
Molecular dynamics
In order to analyse stability of molecular docked complexes of HIVintegrase with H13, NSC91705 and NSC651812 molecular dynamics studies were performed. In this purpose AMBER12 was used for a time span of 50,000ps. Backbone RMSD and RMSF were recorded to observe the complex constancy during simulation time and depicted in Fig. 8 . In visual inspection of the simulation trajectories ( Fig. 8a) 
Conclusion
Pharmacophore-based virtual screening studies were carried out to identify potential molecules for therapeutic application in HIV/AIDS.
Several pharmacophore models were generated using 30 molecules out of 540 compounds in the whole dataset. After analysis of statistical parameters finally 10 hypotheses were considered for further validation. Hypotheses were validated using R 2 pred , s p , R 2 m(test) , Δr 2 m(test) , Fischer's randomization and decoy set, and finally Hypo1 was selected as the best model. The model indicated that HB acceptor and ring aromatic features were critical factors for the inhibitory activity. In order to find out excluded volumes, Hypo1 was used for "hyporefine" and it found several excluded volumes that were important for HIV-integrase activity. Furthermore Hypo1 and Hypo1 with excluded volumes were used for virtual screening of NCI database. From the initial hits, finally two compounds (NSC91705 and NSC651812) were found to be promising HIVintegrase inhibitors after screening with a number of criteria including mapping with omitted feature = 0, comparison of fitscore and estimated activity with most active compound of data set (H13), passing through Lipinski's rule of five and Veber's rule 53 , comparison of dockscore with H13, ADMET and synthetic accessibility analysis. In the molecular docking study, a number of binding interactions were observed between final screened compounds and catalytic amino acid residues of HIV-integrase. The final potential compounds were subjected to 50,000ps molecular dynamics simulation to analyse binding stability in the receptor cavity of HIV-integrase. RMSD, RMSF, potential energy and total energy were recorded of the most active compound and final screened molecules. MD simulation study suggested that complex of NSC651812 achieved stable conformation at lower RMSD of H13 while NSC91705 obtained at higher RMSD value of H13.
Comparison of different parameters of screened compounds with
FDA approved HIV integrase inhibitors confirmed that NSC91705 and NSC651812 were more promising than Dolutegravir, Elvitegravir, Raltegravir. Finally, from the discussion above, it can be postulated that the final screened compounds may be might be promising candidates for the treatment of HIV/AIDS but need further experimental validation for better confirmation.
